Skip to content
    Bristol Myers Squibb logo

    Bristol Myers Squibb

    Lawrenceville, United StatesFounded 1887
    www.bms.comLinkedIn
    Biotech & Life SciencesHealthcare

    Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines in oncology, immunology, cardiovascular, and fibrotic diseases. Through its business development and early innovation arm, it makes strategic equity investments in early- and mid-stage life sciences startups and biotech entrepreneurs.

    54% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 8 prior). Their most common stage is series-b (47% of deals). Average disclosed round size is $122.1M (across 81 rounds with reported amounts).

    Find people at Bristol Myers Squibb on Goldilocks AI

    Portfolio

    71

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    4

    Team

    AL

    Adam Lenkowsky

    Executive Vice President, Chief Commercialization Officer

    Amanda Poole

    Amanda Poole

    Executive Vice President, Chief People Officer

    Cari Gallman

    Cari Gallman

    Executive Vice President, General Counsel and Chief Policy Officer

    Cristian Massacesi, MD

    Cristian Massacesi, MD

    Executive Vice President, Chief Medical Officer and Head of Development

    DE

    David Elkins

    Executive Vice President and Chief Financial Officer

    Greg Meyers

    Greg Meyers

    Executive Vice President, Chief Digital & Technology Officer

    KS

    Karin Shanahan

    Executive Vice President, Chief Supply Chain & Operations Officer

    RP

    Robert Plenge, MD, PhD

    Executive Vice President, Chief Research Officer

    Wendy Short Bartie

    Wendy Short Bartie

    Executive Vice President, Chief Corporate Affairs Officer

    Ben Hickey

    Ben Hickey

    President, RayzeBio

    CB

    Chris Boerner, PhD

    Board Chair and Chief Executive Officer

    Lynelle B. Hoch

    Lynelle B. Hoch

    President, Cell Therapy Organization

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    99 investments
    CompanyRoundAmountDate
    Beeline logoBeelineSeries A$126.3MJun 2026
    Beeline Medicines logoBeeline MedicinesSeries A—Jun 2026
    Precede Bio logoPrecede BioSeries B$63.5MJan 2026
    Beeline Medicines logoBeeline MedicinesSeries A$426.3MJan 2026
    Link Cell Therapies logoLink Cell TherapiesSeries A$60MDec 2025
    Dispatch Biotherapeutics logoDispatch BiotherapeuticsSeries A$216MJul 2025
    DDispatch BioSeries A$216MJul 2025
    GlycoEra logoGlycoEraSeries B$130MMay 2025
    Nuvig Therapeutics logoNuvig TherapeuticsSeries B$161MDec 2024
    Aktis Oncology logoAktis OncologySeries B$175MSep 2024
    ArsenalBio logoArsenalBioUnknown$325MSep 2024
    AArsenal BiosciencesSeries C$325MSep 2024
    ArsenalBio logoArsenalBioSeries C$325MSep 2024
    Outpace logoOutpaceSeries B$144MAug 2024
    Autobahn Therapeutics logoAutobahn TherapeuticsSeries C$100MJul 2024
    Autobahn logoAutobahnSeries C$100MJul 2024
    Envisagenics logoEnvisagenicsSeries B—Jun 2024
    Pathios Therapeutics logoPathios TherapeuticsSeries B$25MApr 2024
    GGRAIL, Inc.Series B$900MMar 2024
    CCour PharmaSeries A$105MJan 2024
    Accent Therapeutics logoAccent TherapeuticsSeries C$75MJan 2024
    Ratio logoRatioSeries B$50MJan 2024
    RRatio Therapeutics Inc.Series B$50MJan 2024
    GlycoEra logoGlycoEraSeries A—Jan 2024
    Asher Bio logoAsher BioSeries C$55MJan 2024
    Page 1 of 4

    Top Co-Investors

    Alexandria Venture Investments20 shared
    ARCH Venture Partners16 shared
    Pfizer Ventures14 shared
    RA Capital Management12 shared
    Novartis Venture Fund8 shared
    Sofinnova Partners8 shared
    Kleiner Perkins8 shared
    Eli Lilly and Company7 shared
    GV7 shared
    Novo Holdings A/S7 shared
    Illumina Ventures6 shared
    Osage University Partners6 shared
    Atlas Venture6 shared
    The Column Group6 shared
    OrbiMed6 shared
    Polaris Partners6 shared
    Novo Capital6 shared
    Takeda Ventures, Inc.6 shared
    Catalio Capital Management6 shared
    Duquesne Family Office5 shared

    Last updated: 7 October 2026